Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Altamira Therapeutics Ltd
(NQ:
CYTO
)
1.500
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, May 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Altamira Therapeutics Ltd
< Previous
1
2
3
4
Next >
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
May 01, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
April 24, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
April 10, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
April 04, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
March 25, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
February 07, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
January 24, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
January 08, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
December 29, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Provides Investor and Business Update
December 11, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
December 05, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
November 29, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business
November 17, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine
November 10, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
September 14, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results
September 12, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th
September 06, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
August 23, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia
July 20, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal
July 17, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering
July 06, 2023
Via
ACCESSWIRE
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration
July 05, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome
June 15, 2023
Via
ACCESSWIRE
Altamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic Targets
May 31, 2023
Via
ACCESSWIRE
Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
May 24, 2023
Via
ACCESSWIRE
Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial Results
May 16, 2023
Via
ACCESSWIRE
Altamira Therapeutics to Host Fiscal Year 2022 Financial Results and Business Update Call on May 16th 2023
May 12, 2023
Via
ACCESSWIRE
Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap Virtual Conference May 10-11
May 01, 2023
Via
ACCESSWIRE
Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed Journal
April 12, 2023
Via
ACCESSWIRE
Altamira Therapeutics Positions its Patented SemaPhore mRNA Delivery Platform as Versatile and Efficient Alternative to Lipid Nanoparticles
April 11, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.